1. Predictive Marker: HER2 in Esophageal Adenocarcinoma.
- Author
-
Subasinghe D, Acott N, and Kumarasinghe MP
- Subjects
- Adenocarcinoma therapy, Antineoplastic Agents pharmacology, Biopsy, Chemotherapy, Adjuvant methods, Esophageal Neoplasms therapy, Esophagoscopy, Esophagus pathology, Esophagus surgery, False Negative Reactions, False Positive Reactions, Humans, Immunohistochemistry instrumentation, Immunohistochemistry methods, In Situ Hybridization instrumentation, Molecular Targeted Therapy methods, Patient Selection, Receptor, ErbB-2 antagonists & inhibitors, Tissue Fixation instrumentation, Tissue Fixation methods, Treatment Outcome, Adenocarcinoma pathology, Antineoplastic Agents therapeutic use, Esophageal Neoplasms pathology, In Situ Hybridization methods, Receptor, ErbB-2 analysis
- Abstract
HER2 positivity is based on the fundamental principle of amplification of the human epidermal growth factor receptor 2 (HER2) gene resulting in overexpression of the protein products . Arising from that a "HER2-positive cancer" is one that shows HER2 gene amplification and resultant protein expression as demonstrated by in situ hybridization and immunohistochemistry, respectively. Testing of the HER2 status is crucial to ensure selection of the correct patient who may benefit from target therapy for esophageal adenocarcinoma. Accurate testing is dependent on several pre-analytical and analytical factors including sample selection, laboratory techniques, and accurate interpretation of HER2 test results.
- Published
- 2018
- Full Text
- View/download PDF